Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVM158 mRNA-LNP vaccine
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal, Intramuscular
01
Overview
EVM158 mRNA-LNP vaccine is a preclinical nucleoside-modified mRNA lipid nanoparticle (LNP) vaccine candidate designed to protect against mousepox, a lethal viral disease caused by the ectromelia virus (ECTV). Developed by researchers at Thomas Jefferson University, the University of Pennsylvania, and Acuitas Therapeutics, the vaccine encodes the ECTV gene EVM158, which is an interferon-gamma binding protein containing the immunodominant CD8+ T-cell epitope TSYKFESV. It is formulated using N1-methylpseudouridine-modified mRNA encapsulated in lipid nanoparticles. The vaccine works by inducing robust, protective memory CD8+ T-cell responses and protective immunity against lethal ECTV infection, serving as a model for the development of CD8+ T-cell-mediated vaccines against other poxviruses, such as variola virus and monkeypox.
- Other names
- EVM158 mRNA vaccineEVM-158 mRNA vaccineEVM 158 mRNA vaccine
Beyond the preview
Go deeper on EVM158 mRNA-LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVM158 mRNA-LNP vaccine.